Skip to main content
Premium Trial:

Request an Annual Quote

Reports Tout Return on NIH's Investment

According to a new report from the advocacy group United for Medical Research, and authored by economist Everett Ehrilich, because of the National Institutes of Health's investments, "the cost of sequencing a genome has fallen from over $100 million at the beginning of the last decade to about $20,000 today," and further, it's predicted that "the sequencing business will grow by 20 percent a year and become a $1.7 billion industry by 2015." The Wall Street Journal adds that NIH's $3.8 billion investment in the Human Genome Project, "along with subsequent capital provided by the government and the private sector, generated a total return of roughly $49 billion in direct and indirect federal tax revenues over the last two decades or so," according to a separate report authored by the nonprofit Battelle Memorial Institute, with support from Life Technologies. Daily Scan's sister publication GenomeWeb Daily News has more on the Battelle report here.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.